Cagrilintide and semaglutide target different hunger-signaling pathways — one mimics amylin, the other activates GLP-1 receptors. REDEFINE trial data shows the combination produced greater average weight reduction than semaglutide alone. Access to either requires medical approval by a licensed provider. TelosRX offers asynchronous evaluations.
If you follow obesity medicine research, 2025 was the year cagrilintide moved from a footnote to a headline. Novo Nordisk's REDEFINE program published Phase 3 trial results showing the combined therapy — branded CagriSema — outperformed semaglutide alone by a meaningful margin. That triggered a flood of patient questions: what's the difference, which should I ask about, and is any of this available?
This article breaks it down: mechanisms, trial data, side effects, and what "which to consider" actually means in a clinical context.
What Is Cagrilintide?
Cagrilintide is a long-acting synthetic amylin analog. Amylin is a hormone your pancreatic beta cells release alongside insulin — it signals the brain to slow gastric emptying and reduce appetite. Cagrilintide mimics and extends that signal with once-weekly subcutaneous dosing.
It targets a receptor pathway entirely separate from GLP-1. That's the key point: it's not just a different drug in the same class. It's a different mechanism layered on top of what GLP-1 agonists already do.
Cagrilintide is not FDA-approved for any indication. It is not commercially available as a standalone product. Any clinical access to it would require a licensed provider's evaluation and, if appropriate, a prescription for a compounded formulation under federal compounding regulations — which is distinct from any FDA-approved drug.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — the same class as liraglutide, but with a longer half-life that enables weekly dosing. It mimics glucagon-like peptide-1, a gut-released hormone that slows gastric emptying, signals satiety in the brain, and stimulates insulin secretion in response to meals.
Brand-name semaglutide (Ozempic for T2D, Wegovy for obesity) is FDA-approved. Compounded semaglutide — prepared by a licensed pharmacy under federal compounding regulations — is not FDA-approved but has been widely accessible through telehealth pharmacies. See TelosRX's compounded semaglutide guide for context on how access works today.
Cagrilintide vs Semaglutide: Side-by-Side Comparison
| Feature | Cagrilintide | Semaglutide |
|---|---|---|
| Drug class | Amylin receptor agonist | GLP-1 receptor agonist |
| Target pathway | Amylin / CGRP receptor | GLP-1 receptor |
| Dosing | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| FDA approval | Not approved (investigational) | Approved (brand); compounded = not FDA-approved |
| Mean weight loss (monotherapy, trials) | ~8–10% body weight | ~13–15% body weight (Wegovy 2.4 mg) |
| Mean weight loss (CagriSema combo) | ~20.4% (REDEFINE 1, non-T2D adults) | |
| Glycemic effect | Moderate via amylin pathway | Strong; approved for T2D (Ozempic) |
| Top side effects | Nausea, injection-site reactions | Nausea, vomiting, diarrhea, constipation |
| Commercial availability | Not commercially available | Brand-name + compounded (Rx required) |
REDEFINE Trial Results: What the Data Found
The REDEFINE program is the largest clinical dataset directly comparing CagriSema to semaglutide. REDEFINE 1 enrolled adults with overweight or obesity but without type 2 diabetes. At 68 weeks, mean body weight change was −20.4% with CagriSema versus −3.0% with placebo — roughly 5–8 percentage points more than semaglutide monotherapy at equivalent doses. Full results are available in The New England Journal of Medicine: REDEFINE 1 and REDEFINE 2.
REDEFINE 2 focused on adults with type 2 diabetes. Of CagriSema participants, 74% achieved an HbA1c of ≤6.5% by week 68 — compared to 15.9% on placebo. A 2025 meta-analysis on PubMed reviewing CagriSema versus semaglutide confirmed the combination produced meaningful additional weight reduction across trials.
These are population-level trial averages, not individual outcome guarantees. Individual results vary based on metabolic health, adherence, dose titration, and many other factors.
Side Effects Compared
Both agents slow gastric emptying, so nausea is the most common complaint with each. When combined, the GI side-effect rate climbed: REDEFINE 1 reported gastrointestinal adverse events in 79.6% of CagriSema participants (mostly mild-to-moderate and transient) versus lower rates with semaglutide alone.
- Semaglutide alone: nausea, vomiting, diarrhea, constipation — well-characterized from large Wegovy/Ozempic trials
- Cagrilintide alone: nausea, injection-site reactions, reduced appetite
- CagriSema combo: additive GI effects; more injection-site reactions than semaglutide alone
Provider-guided dose titration — starting low and increasing slowly — is the standard approach to managing tolerability with both agents. Any reported side effect warrants a conversation with your prescribing provider.
Which to Consider?
This is a clinical decision, not a self-selection exercise. Semaglutide has a far longer track record of accessible compounded prescribing. Cagrilintide in any form is not commercially available and would require a compounding pharmacy able to prepare it under federal regulations — and even then, only with a licensed provider's evaluation and provider-issued prescription.
If you're exploring weight management options, the practical path starts with an asynchronous health evaluation. A licensed provider reviews your history, any metabolic labs, and your goals — then determines what (if anything) is clinically appropriate. That's true whether you're asking about semaglutide, tirzepatide, or emerging compounds like cagrilintide.
Read how that works at TelosRX's GLP-1 comparison guide, or review the detailed REDEFINE trial breakdown for the full cagrilintide dataset. Start your private evaluation at TelosRX — no video call required.
Frequently Asked Questions
What is the difference between cagrilintide and semaglutide?
Semaglutide is a GLP-1 receptor agonist that mimics a gut hormone to reduce appetite and slow digestion. Cagrilintide is an amylin analog that works on a different receptor pathway — targeting satiety signals originating in pancreatic amylin biology. The two complement each other, which is why the combination (CagriSema) showed additive effects in Phase 3 trials.
Is cagrilintide available in the US in 2026?
CagriSema as a branded combination therapy is not FDA-approved as of mid-2026. Cagrilintide as a compounded peptide is also not FDA-approved. Access to any compounded formulation requires evaluation and a provider-issued prescription through a licensed compounding pharmacy. Your eligibility depends on your individual health profile as reviewed by a licensed provider.
Is CagriSema more effective than semaglutide alone?
REDEFINE trial data suggests it is, on average: CagriSema produced approximately 20.4% mean body weight reduction versus roughly 13–15% with semaglutide alone at similar doses. However, the combination also carried a higher rate of gastrointestinal side effects. Clinical appropriateness depends on the individual — a licensed provider must evaluate whether the benefit-risk profile fits your situation.
What are the side effects of CagriSema?
The most commonly reported side effects in REDEFINE trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation — affecting approximately 79.6% of CagriSema participants, most mild to moderate. Injection-site reactions were also higher with the combination. Slow dose titration under provider guidance is standard practice for managing tolerability.
Can I get cagrilintide through a telehealth pharmacy?
Any compounded peptide medication — including cagrilintide — requires evaluation by a licensed provider and a provider-issued prescription. TelosRX's evaluation process is fully asynchronous: you complete a health questionnaire, a licensed provider reviews it, and if clinically appropriate, medication ships from a licensed pharmacy. Approval is not guaranteed.
How does semaglutide compare to CagriSema for type 2 diabetes?
Semaglutide (Ozempic) has FDA-approved indications for type 2 diabetes. In REDEFINE 2, the CagriSema combination achieved HbA1c ≤6.5% in 74% of T2D participants versus 15.9% on placebo — a substantial glycemic benefit. CagriSema is not FDA-approved for any indication. Any medication decision for T2D management requires a prescribing provider's evaluation.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.